返回 
加入收藏
普芦卡必利治疗慢性便秘的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 普芦卡必利治疗慢性便秘的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察普芦卡必利治疗慢性便秘（CC）的疗效及安全性。方法：选取2016年6月－2017年1月于我院肛肠科就诊的CC患者100例，按随机数字表法分为对照组和观察组，各50例。对照组患者口服枸橼酸莫沙必利片5 mg+乳果糖口服溶液10 mL，每日3次；观察组患者口服琥珀酸普芦卡必利片2 mg，每日1次。两组患者均连续治疗4周。观察两组患者的临床疗效以及治疗前后血清炎症因子[白细胞介素6（IL-6）、肿瘤坏死因子α（TNF-α）、干扰素γ（IFN-γ）]水平、结肠传输时间（全结肠传输时间、左半结肠传输时间、右半结肠传输时间、直肠乙状结肠传输时间），并记录排便障碍和不良反应的发生情况。结果：两组均未见治愈患者；观察组患者的总有效率为94.00％，显著高于对照组的78.00％，差异有统计学意义（P＜0.05）。治疗前，两组患者的血清炎症因子水平、结肠传输时间比较，差异均无统计学意义（P＞0.05）。治疗后，对照组患者IL-6、IFN-γ水平和观察组患者IL-6、TNF-α、IFN-γ水平均显著下降，且观察组IL-6、TNF-α、IFN-γ水平均显著低于对照组；两组患者结肠传输时间均显著缩短，且观察组显著短于对照组，差异均有统计学意义（P＜0.05）。治疗后，观察组患者排便费力、排空不全、梗阻感、肛门坠胀感的发生率均显著低于对照组，差异均有统计学意义（P＜0.05）。两组患者治疗后便不尽感的发生率及不良反应的发生率比较，差异均无统计学意义（P＞0.05）。结论：与莫沙必利联合乳果糖的传统治疗方案比较，普芦卡必利可有效降低CC患者血清炎症因子水平，缩短结肠传输时间，减少排便费力、排空不全等排便障碍症状的发生，且安全性与之相当。 |
| ABSTRACT： | OBJECTIVE： To observe therapeutic efficacy and safety of prucalopride in the treatment of chronic constipation （CC）. METHODS： Totally of 100 CC patients were selected from anorectal department of our hospital during Jun. 2016-Jan. 2017， and then divided into control group and observation group according to random number table， with 50 cases in each group. Control group was given Mosapride citrate tablets 5 mg +Lactulose oral solution 10 mL orally， 3 times a day. Observation group was given Prucalopride succinate tablets 2 mg orally， once a day. Both groups were treated for consecutive 4 weeks. Clinical efficacies of 2 groups were observed， and the levels of serum inflammatory factors （IL-6， TNF-α， IFN-γ） and colonic transit time （total colonic transit time， left colonic transit time， right colonic transit time， rectosigmoid colonic transit time） were observed before and after treatment. The occurrence of defecation disorders and ADR were recorded. RESULTS： None of patient in 2 groups was cured. Total response rate of observation group was 94.00％， which was significantly higher than 78.00％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in the levels of serum inflammatory factors or colonic transit time （P＞0.05）. After treatment， the levels of IL-6 and IFN-γ in control group， the levels of IL-6， TNF-α and IFN-γ in observation group were decreased significantly， and the levels of IL-6， TNF-α and IFN-γ in observation group were significantly lower than those of control group； the colonic transit time in 2 groups was shortened significantly， and observation group was significantly shorter than control group， with statistical significance （P＜0.05）. After treatment， the incidence of defecation， incomplete emptying， sense of obstruction and sense of rectal tenesmus in observation group were significantly lower than control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of sense of rectal tenesmus after treatment or ADR between 2 groups （P＞0.05）. CONCLUSIONS： Compared with traditional plan of mosapride combined with lactulose， prucalopride can more effectively reduce the levels of serum inflammatory factors， shorten colonic transit time， reduce the occurrence of defecation disorders as defecation and incomplete emptying， with equivalent safety. |
| 期刊： | 2018年第29卷第12期 |
| 作者： | 郭伶俐，李红岩，卞红磊，张燕，于溯洋，李萌 |
| AUTHORS： | GUO Lingli，LI Hongyan，BIAN Honglei，ZHANG Yan，YU Suyang，LI Meng |
| 关键字： | 普芦卡必利；莫沙必利；乳果糖；慢性便秘；炎症因子；结肠传输时间；排便障碍；不良反应 |
| KEYWORDS： | Prucalopride； Mosapride； Lactulose； Chronic constipation； Inflammatory factors； Colonic transit time； Defecation disorder； ADR |
| 阅读数： | 1153 次 |
| 本月下载数： | 8 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
